title: Vascular catabolism of bradykinin in the isolated perfused rat kidney.
abstract: Kinins in the circulation are rapidly metabolized by several different peptidases. The purpose of this study was to evaluate the contribution of membrane-bound peptidases to kinin metabolism in the renal circulation. Experiments were performed in vitro, in isolated rat kidneys perfused at a constant flow rate (8 ml/min) with Tyrode's solution. The effects of peptidase inhibitors were evaluated on the functional vasodilator response caused by bradykinin (30 nM) or [Tyr(Me)(8)]bradykinin (10 nM) via activation of bradykinin B2 receptors in kidneys precontracted with prostaglandin F2alpha. Angiotensin converting enzyme inhibitors, enalaprilat (3 microM), ramiprilat (1 microM) or lisinopril (1 microM), increased the bradykinin-induced renal vasodilation by 40% or more. Inhibitors of neutral endopeptidase (thiorphan or phosphoramidon, 10 microM), basic carboxypeptidase (DL-2-mercaptomethyl-3-guanidino-ethylthiopropanoic acid or MGTPA, 10 microM) and aminopeptidase P (apstatin, 20 microM) however did not enhance the renal vasodilator response elicited by kinins, whatever tested alone or in the presence of lisinopril. These findings indicate that angiotensin converting enzyme is the major peptidase whose inhibition potentiates the renal bradykinin B2 receptor mediated vasodilator response of kinins. The relative contribution in this potentiation of inhibition of kinin inactivation and of cross-talk of angiotensin converting enzyme with bradykinin B2 receptor remains however to be clarified.
authors.affiliation: Institut de Pharmacologie, Faculté de Médecine, 11 Rue Humann, 67085 Cedex, Strasbourg, France.
authors.forename: K
authors.initials: K
authors.lastname: Bagaté
authors.forename: L
authors.initials: L
authors.lastname: Develioglu
authors.forename: M
authors.initials: M
authors.lastname: Grima
authors.forename: W
authors.initials: W
authors.lastname: De Jong
authors.forename: W H
authors.initials: WH
authors.lastname: Simmons
authors.forename: J L
authors.initials: JL
authors.lastname: Imbs
authors.forename: M
authors.initials: M
authors.lastname: Barthelmebs
mesh_terms: D000626:Aminopeptidases / Q000037:antagonists & inhibitors; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology*; D000818:Animals; D001920:Bradykinin / Q000378:metabolism / Q000494:pharmacology*; D002268:Carboxypeptidases / Q000037:antagonists & inhibitors; D007668:Kidney / Q000187:drug effects* / Q000378:metabolism; D008297:Male; D011480:Protease Inhibitors / Q000494:pharmacology; D051381:Rats; D017208:Rats, Wistar; D043782:Receptor, Bradykinin B2; D018002:Receptors, Bradykinin / Q000187:drug effects / Q000378:metabolism; D014661:Vasoconstriction / Q000187:drug effects* / Q000502:physiology; D014664:Vasodilation / Q000187:drug effects* / Q000502:physiology
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D011480:Protease Inhibitors; D043782:Receptor, Bradykinin B2; D018002:Receptors, Bradykinin; D002268:Carboxypeptidases; D000626:Aminopeptidases; D001920:Bradykinin